[go: up one dir, main page]

WO2017141204A3 - Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament - Google Patents

Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament Download PDF

Info

Publication number
WO2017141204A3
WO2017141204A3 PCT/IB2017/050909 IB2017050909W WO2017141204A3 WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3 IB 2017050909 W IB2017050909 W IB 2017050909W WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3
Authority
WO
WIPO (PCT)
Prior art keywords
entry
promoting
agent
relates
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/050909
Other languages
English (en)
Other versions
WO2017141204A2 (fr
Inventor
Kantaraja CHINDERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017141204A2 publication Critical patent/WO2017141204A2/fr
Publication of WO2017141204A3 publication Critical patent/WO2017141204A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés et des procédés ayant des propriétés de promotion d'entrée (généralement désignées d'administration de médicament). Elle concerne en particulier des agents favorisant l'entrée pour l'administration de protéines, de polypeptides et d'analogues; des acides nucléiques et analogues; des petites molécules (souvent désignées médicaments comprenant des agents antimicrobiens) ayant des applications dans la recherche ou des utilisations médicinales/thérapeutiques. Plus spécifiquement, l'invention concerne des polymères, des protéines, des polypeptides ou des peptides naturels biodégradables existants ou des biopolymères synthétiques décorés de biguanidine. L'invention concerne également le procédé de synthèse/modification de biomolécules avec de la biguanidine. Un autre aspect de l'invention concerne la composition et le procédé de promotion de l'entrée (administration) d'agents thérapeutiques ou prophylactiques ou d'agents d'imagerie ou d'agents utilisés dans la recherche ou la thérapie. Le procédé de promotion de l'entrée d'un agent (agent introduit) dans une cellule eucaryote ou procaryote, le procédé comprenant l'étape consistant à exposer la cellule à l'agent introduit en présence d'un agent favorisant l'entrée, l'agent favorisant l'entrée comprenant un (glucide ou protéine, polypeptide ou peptide ou polyamine) naturel,linéaire et/ou ramifié ou dendrimère, naturel, un polymère synthétique ou semi-synthétique (polymères portant une amine) ayant des fractions biguanidine substituées (0,01 à 100 %).
PCT/IB2017/050909 2016-02-17 2017-02-17 Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament Ceased WO2017141204A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641005523 2016-02-17
IN201641005523 2016-02-17

Publications (2)

Publication Number Publication Date
WO2017141204A2 WO2017141204A2 (fr) 2017-08-24
WO2017141204A3 true WO2017141204A3 (fr) 2017-09-28

Family

ID=59624833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/050909 Ceased WO2017141204A2 (fr) 2016-02-17 2017-02-17 Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament

Country Status (1)

Country Link
WO (1) WO2017141204A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873541A4 (fr) * 2018-10-30 2022-08-31 Ohio State Innovation Foundation Nanoparticules activées par ph
KR102371859B1 (ko) * 2020-06-12 2022-03-07 연세대학교 산학협력단 화학적 교환에 의한 포화 전이 자기 공명 이미징용 조영제 및 이를 이용하는 화학적 교환에 의한 포화 전이 자기 공명 이미징 방법
CN113930454A (zh) * 2021-11-26 2022-01-14 南通大学 壳聚糖-聚二甲双胍在作为基因转染试剂方面的应用
CN114478834B (zh) * 2022-02-28 2023-08-08 江南大学 一种胍基透明质酸抗菌聚合物及其制备方法和应用
CN114561046B (zh) * 2022-02-28 2023-10-27 江南大学 一种胍基透明质酸型抗菌水凝胶及其制备方法和应用
EP4525827A1 (fr) * 2022-04-24 2025-03-26 Peptomer Therapeutics Private Limited Peptidomimétiques cationiques de synthèse, leurs dérivés et leur préparation conjointement à des compositions pour diverses applications médicales
CN116637173B (zh) * 2023-05-11 2024-03-22 南京医科大学附属口腔医院 一种多胍抗菌肽口腔微针
CN117384969A (zh) * 2023-10-11 2024-01-12 上海市第六人民医院 一种转染试剂及其制备方法与应用
CN119033929B (zh) * 2023-10-18 2025-11-07 暨南大学 一种功能化修饰的超支化聚精胺及制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054123A1 (fr) * 2011-10-11 2013-04-18 The Royal Veterinary College Procédés

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054123A1 (fr) * 2011-10-11 2013-04-18 The Royal Veterinary College Procédés

Also Published As

Publication number Publication date
WO2017141204A2 (fr) 2017-08-24

Similar Documents

Publication Publication Date Title
WO2017141204A3 (fr) Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament
Zhang et al. Dynamic covalent polymers for biomedical applications
Wang et al. Recent advances in the fabrication, functionalization, and bioapplications of peptide hydrogels
Huang et al. Supramolecular hydrogels with reverse thermal gelation properties from (oligo) tyrosine containing block copolymers
Michels et al. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis
Xie et al. Calcium-ion-triggered co-assembly of peptide and polysaccharide into a hybrid hydrogel for drug delivery
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
ATE312628T1 (de) Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägers
WO2007043048A3 (fr) Hydrogels auto-assembles et leurs procedes d'elaboration et d'utilisation
BR112014014599A2 (pt) polímeros de alfa-aminoamidina e uso dos mesmos
BR112015023168A8 (pt) composição de dicetopiperazina cristalina, métodos de produção de partículas de dicetopiiperazina,de produção de uma composição e de tratamento e uso de uma composição de dicetopiperazina cristalina
EP2476695A3 (fr) Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
MX2009011813A (es) Acidos poliglutamicos funcionalizados con grupos cationicos y grupos hidrofobicos y aplicaciones de los mismos, en particular aplicaciones terapeuticas de los mismos.
Ho et al. Tunable surface charge enables the electrostatic adsorption-controlled release of neuroprotective peptides from a hydrogel–nanoparticle drug delivery system
Yishay‐Safranchik et al. Controlled release of doxorubicin and Smac‐derived pro‐apoptotic peptide from self‐assembled KLD‐based peptide hydrogels
FR2885130B1 (fr) Procede de preparation de polylysines dendrimeres greffes
Chang et al. Preparation and characterization of a novel thermosensitive hydrogel based on chitosan and gelatin blends
Sun et al. Self-sorting microscale compartmentalized block copolypeptide hydrogels
Tian et al. Natural electroactive hydrogel from soy protein isolation
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
Hoque et al. Microgel-assisted delivery of adenosine to accelerate fracture healing
Clapacs et al. Coiled coil crosslinked alginate hydrogels dampen macrophage-driven inflammation
Wei et al. Degradable poly (amino acid) vesicles modulate DNA-induced inflammation after traumatic brain injury
Kong et al. Synthetic polypeptide bioadhesive based on cation− π interaction and secondary structure
Biscari et al. Antibacterial Broad‐Spectrum Dendritic/Gellan Gum Hybrid Hydrogels with Rapid Shape‐Forming and Self‐Healing for Wound Healing Application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17752778

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17752778

Country of ref document: EP

Kind code of ref document: A2